DHEA (Dehydroepiandrosterone) – Off-Label
PharmaceuticalThe medical score is slightly higher than the community score: while clinical studies demonstrate clear indications (adrenal insufficiency, vaginal atrophy) with measurable effects [s4, s10], community users more frequently report unwanted hormonal disturbances and uncertainty regarding correct dosing without medical supervision [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
DHEA is an adrenal prohormone peripherally converted to androgens and estrogens, with established clinical use in adrenal insufficiency and vaginal atrophy. It circulates primarily as the sulfated ester DHEA-S, activated tissue-specifically by sulfatases. Evidence for off-label applications such as anti-aging or cognitive enhancement remains weak and inconsistent. The risk profile includes androgen-dependent side effects and potential hormonal interference.
Description
DHEA is an adrenal steroid hormone and prohormone for androgens/estrogens; clinically relevant in adrenal insufficiency and menopausal atrophy [s1, s3].
Dehydroepiandrosterone (DHEA) is the most abundant circulating steroid hormone in the human body, produced primarily in the zona reticularis of the adrenal cortex under ACTH control [s1, s2]. Small amounts are also synthesized in the gonads and brain [s1]. DHEA and its sulfate ester DHEA-S serve as precursors for the intracellular biosynthesis of androgens (testosterone) and estrogens (estradiol) in peripheral tissues [s1, s3]. Endogenous DHEA production peaks in the third decade of life and subsequently declines continuously, such that 70-year-olds exhibit only approximately 10–20% of peak values [s2]. Clinical indications include: - Adrenal insufficiency (primary and secondary): improvement of quality of life and well-being [s4, s5] - Menopausal symptoms / vaginal atrophy: Intrarosa® (prasterone 6.5 mg intravaginal) is FDA-approved for dyspareunia [s10, s11] - Off-label: anti-aging, libido enhancement, depression, bone density, body composition, cognitive function [s5, s6, s7, s8] Off-label use is widespread in the general population (particularly in the USA and biohacking communities), with scientific evidence varying considerably by indication [s5, s9]. Clinical evidence is strongest for women with adrenal insufficiency and postmenopausal women with sexual dysfunction [s4, s5].
Legal Status (DE)
In Germany, the Joint Expert Commission (BVL/BfArM) classifies DHEA-containing products as medicinal products at daily doses of 10 mg or above [s12]. Below this threshold, DHEA is considered an unauthorized novel food ingredient and is not marketable in dietary supplements [s12, s13]. DHEA falls under the German Medicines Act (AMG) and is prescription-only; importation from non-EU countries (e.g., the USA, where DHEA is available over the counter) may be legally problematic [s13, s14]. Furthermore, DHEA is prohibited for athletes under the WADA list as an anabolic agent [s15]. As an approved medicinal product (prasterone/Intrarosa® 6.5 mg intravaginal), it holds FDA approval for moderate to severe dyspareunia due to menopausal vaginal atrophy [s10]; EMA approval exists for the vaginal formulation.
Mechanism of Action
DHEA is synthesized from cholesterol via pregnenolone in the zona reticularis of the adrenal cortex; the enzyme CYP17A1 (17α-hydroxylase/17,20-lyase) catalyzes the final step [s1, s2, s3]. In blood, approximately 95% of DHEA circulates as the sulfated ester (DHEA-S), which serves as a stable reservoir and is converted to active DHEA by steroid sulfatases as needed [s1]. In peripheral tissues (skin, liver, adipose tissue, bone, brain), DHEA is converted by tissue-specific enzymes to biologically active androgens (primarily testosterone, dihydrotestosterone) and estrogens (primarily estradiol). This process is termed intracrinology [s3, s5]. Additionally, DHEA acts directly via several receptor pathways [s3]: - As a weak agonist at androgen and estrogen receptors - As a modulator of GABA-A receptors (neurosteroid-like effect) - As a sigma-1 receptor agonist (possible neuroprotective effect) - Activation of PPAR-alpha (metabolic effects) Following oral administration, DHEA is rapidly absorbed and sulfated to DHEA-S in the liver and intestine [s1]. The biological half-life of DHEA-S is 8–11 hours [s1].
Dosing
Nebenniereninsuffizienz (addissonsche Krankheit, sekundäre NNI)
- Dose
- 25–50 mg elemental DHEA
- Frequency
- 1× täglich morgens
- Route
- oral
- Duration
- langfristig unter ärztlicher Kontrolle
- Timing
- Morning with meal (circadian adjustment)
- With food
- empfohlen
Postmenopausale sexuelle Dysfunktion / vaginale Atrophie (zugelassen)
- Dose
- 6.5 mg prasterone intravaginal (Intrarosa®)
- Frequency
- 1× täglich abends
- Route
- oral
- Duration
- mindestens 12 Wochen, Langzeitanwendung möglich
- Timing
- In the evening before bedtime
- With food
- optional
Off-Label: Anti-Aging / Libido / Stimmung (postmenopausal)
- Dose
- 25–50 mg
- Frequency
- 1× täglich morgens
- Route
- oral
- Duration
- 3–6 Monate, dann Pause und Neubewertung
- Timing
- morning, fasted or with meal
- With food
- optional
The BfR notes that as little as 25 mg DHEA/day can produce measurable changes in hormone levels in postmenopausal women [s13]. In Germany, the medicinal product classification applies from a daily dose of 10 mg [s12]. Higher doses (>50 mg) are not advisable without medical supervision. Long-term data for doses above 50 mg are largely lacking [s5].
DHEA-S serum levels should be measured prior to supplementation. Follow-up monitoring after 8–12 weeks is recommended. In Germany, DHEA is not legally available without a prescription (medicinal product classification applies from a daily dose of 10 mg) [s12, s13].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Androgenisierung bei Frauen (Akne, Hirsutismus, Haarausfall/Alopezie) Conversion of DHEA to androgens (primarily testosterone, DHT) can cause androgenic side effects, particularly in women and at higher doses [s5, s13]. | gelegentlich | moderat |
| Ödeme / Wassereinlagerungen Estrogen-like effects via peripheral conversion may promote water retention [s5]. | gelegentlich | leicht |
| Stimmungsschwankungen, Reizbarkeit, Manie (bei Kombination mit Antidepressiva) DHEA has triggered mania in individuals taking antidepressants [s16]. Neurosteroid activity via GABA-A and sigma-1 receptors [s3]. | gelegentlich | moderat |
| Veränderung der Libido (Steigerung oder Verlust) Hormonal conversion can have libido-stimulating or -suppressing effects; individual variation is considerable [c1, c2]. | gelegentlich | leicht |
| Erhöhte Herzfrequenz / Palpitationen Reported in some user accounts; mechanistically plausible via adrenergic activation [s5]. | selten | leicht |
| Lebertoxizität bei Langzeitanwendung (unkontrolliert) Uncontrolled long-term use has been associated with hepatotoxic changes; the BfR has highlighted this risk [s14]. | selten | schwer |
| Erhöhtes Risiko hormonsensibler Karzinome (Brust, Prostata) bei Langzeitanwendung High-dose or long-term DHEA use may increase the risk of hormone-sensitive carcinomas; robust long-term data are lacking [s13, s16, s17]. | theoretisch | schwer |
| Insulinresistenz / Glukosestoffwechselstörung DHEA can convert to androgens that affect insulin sensitivity; diabetics should monitor blood glucose closely [s17]. | theoretisch | moderat |
Contraindications
DHEA elevates estrogen and androgen levels and may stimulate hormone-dependent tumors [s13, s16, s17].
Insufficient safety data; hormonal interference with fetal development possible [s5].
Pre-existing hyperandrogenemia may be exacerbated by DHEA supplementation [s5].
DHEA is hepatically metabolized; hepatic dysfunction increases the risk of accumulation and hepatotoxic effects [s14].
DHEA has triggered manic episodes in predisposed individuals [s16].
DHEA can affect insulin action and destabilize blood glucose levels [s17].
Interactions
Synergistic
In patients with adrenal insufficiency, DHEA is used as an adjunct to cortisol replacement therapy; may improve quality of life [s4, s5].
Combination therapies in menopause studies demonstrate additive effects on libido and well-being [s5].
DHEA and enclomiphene act synergistically on male hormonal balance. DHEA provides precursor hormones, while enclomiphene stimulates endogenous testosterone production via the hypothalamic-pituitary-gonadal axis. Compounded formulations containing both substances show improvements in testosterone levels and well-being.
DHEA and pregnenolone together form a synergistic hormonal cascade. Pregnenolone is the direct precursor of DHEA, and both together can support adrenal hormone production and improve energy and well-being.
DHEA and ashwagandha can synergistically improve the cortisol/DHEA ratio, which is considered a biomarker of healthy aging. Ashwagandha reduces HPA axis activity and cortisol levels, while DHEA supplementation directly raises the DHEA/cortisol balance. Together they support a balanced stress hormone profile.
DHEA is converted to estrogens in the body; DIM shifts estrogen metabolism toward more favorable metabolites (2-hydroxyestrone) and away from less favorable ones (16α-hydroxyestrone). The combination may support balanced estrogenic activity, particularly in DHEA users with elevated estrogen levels.
Apigenin inhibits the aromatase enzyme and can attenuate the conversion of DHEA metabolites (androgens) to estrogens. This may be beneficial in men or postmenopausal women taking DHEA who wish to avoid elevated estrogen levels.
Caution
DHEA may increase bleeding tendency in patients on anticoagulants; close INR monitoring required [s16].
DHEA has triggered mania in patients on antidepressants; combination requires close monitoring [s16].
DHEA may antagonize the anti-estrogenic effects of tamoxifen and aromatase inhibitors [s16].
DHEA may increase plasma concentrations of triazolam [s16].
DHEA may affect blood glucose; dose adjustment of oral antidiabetic agents may be necessary [s17].
DHEA may reduce the efficacy of BCG vaccination [s16].
Concurrent use of DHEA and HCG may affect SHBG levels. High DHEA doses can lower SHBG, which in the setting of already low SHBG and HCG therapy may result in disproportionately elevated free testosterone. Close hormonal monitoring is recommended.
Studies
Tier A — High Evidence
Outcome: Quality of life, sexual function, bone density in postmenopausal women (normal adrenal function)
Effect Size: Small to moderate effects on sexual function; inconsistent effects on other endpoints
Outcome: Depressive symptoms in various populations
Effect Size: Significant improvement vs. placebo (p < 0.05); exact effect size varies by population
Outcome: Cognitive function and quality of life in older adults
Effect Size: No significant difference between DHEA and placebo for cognitive endpoints
Outcome: Cognitive function in postmenopausal women
Effect Size: Inconsistent results; no clear cognitive benefit established
Outcome: Most bothersome symptom (dyspareunia, vaginal dryness) in menopausal atrophy
Effect Size: Significant improvement vs. placebo; FDA approval based on these data
Outcome: Bone mineral density and body composition
Effect Size: Sex-specific effects: women showed protection against menopause-related BMD loss
Tier B — Moderate Evidence
Outcome: Testosterone levels following DHEA supplementation (dose-response)
Effect Size: Dose-dependent increase in testosterone; stronger effect in women than in men
Tier C — Low Evidence
Outcome: Mechanistic overview of DHEA receptor effects
Community Evidence
Top reported benefits
- Increased energy and vitality
- Improved libido
- Improved mood and well-being
- Subjective increase in muscle strength
- Improved sleep (in isolated cases)
Top reported issues
- Hair loss / alopecia (particularly in women)
- Acne and oily skin
- Hormonal dysregulation (DHEA-S elevated, LH/FSH disturbances)
- Weight gain and water retention
- Mood swings and irritability
- Increased perspiration / hot flashes
Several community users report unmonitored use without prior blood testing, resulting in marked hormonal fluctuations [c2, c3]. One user reported persistent hormonal dysregulation after only 25 mg daily [c3]. German forums repeatedly highlight the legal grey area and increased cancer risk with long-term use [c4]. The polarization between enthusiastic long-term users (20+ years, no problems) [c1] and users experiencing serious adverse effects is notable.
Scientific Sources
- Dehydroepiandrosterone – Wikipedia (biological overview)
Wikipedia Contributors (2024). WikipediaCLink - Clinical Review – Prasterone (Intrarosa)
FDA Center for Drug Evaluation and Research (2016). NCBI Bookshelf / FDA NDA 208470ALink - FDA Application Number 208470Orig1s000 – Prasterone (Intrarosa) Summary Review
FDA CDER (2016). FDA Drug Approval PackageALink - Einstufung von Dehydroepiandrosteron – Gemeinsame Expertenkommission BVL/BfArM
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2025). BVL FachmeldungenALink - Anti-Aging-Hormon DHEA – Verbraucherzentrale
Verbraucherzentrale Deutschland (2024). Verbraucherzentrale.deBLink - Ist der Import von DHEA als Nahrungsergänzungsmittel strafbar (wegen Doping-Verdacht)?
Frag-einen-Anwalt.de (juristische Auskunft) (2023). Frag-einen-Anwalt.deCLink - List of Drugs Banned by the World Anti-Doping Agency – DHEA as anabolic agent
Wikipedia Contributors / WADA (2025). WADA Prohibited List / WikipediaBLink - Dehydroepiandrosterone (DHEA) – Drug Interactions and Safety
MSD Manual Profi-Ausgabe / Merck Manual Professional (2024). MSD ManualBLink - DHEA – Overview, Uses, Side Effects, Precautions, Interactions, Dosing
WebMD Editorial Team (2024). WebMD / MedlineCLink - The Sex Hormone Precursors DHEA and DHEAS: Molecular Mechanisms and Actions on Human Body
Benmassaoud A, Ghazali M, Aljohani N, et al. (2025). International Journal of Molecular SciencesBLink - DHEA supplementation for cognitive function in healthy elderly people (Cochrane-related review)
Grimley Evans J, Malouf R, Huppert F, et al. (2022). PMC / Cochrane relatedALink - Adrenal Androgens and Aging
Kamel NS, Gammack JK (2006). Endotext / NCBI BookshelfBLink - The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors
Nair KS, Rizza RA, O'Brien P, et al. (2008). Receptors & Channels / PMCBLink - Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women – position statement of expert panel of Polish Menopause and Andropause Society
Donovitz GS, Weidner Morpurgo L, Katz T, et al. (2020). Ginekologia PolskaAPMID:33030737 - The Benefits and Harms of Systemic Dehydroepiandrosterone (DHEA) in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Meta-analysis
Elraiyah T, Sonbol MB, Wang Z, et al. (2014). Journal of Clinical Endocrinology & MetabolismALink - Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trial
Kritz-Silverstein D, Von Mühlen D, Barrett-Connor E, et al. (2008). Journal of the American Geriatrics SocietyADOI - Effect of dehydroepiandrosterone therapy on cognitive performance among postmenopausal women: a systematic review of randomized clinical trial data
Gleason CE, Dowling NM, Wharton W, et al. (2023). MenopauseAPMID:37788418 - Sex-specific Effects of DHEA on Bone Mineral Density and Body Composition: A Pooled Analysis of Four Clinical Trials
Jankowski CM, Wolfe P, Schmiege SJ, et al. (2019). Journal of Clinical Endocrinology & MetabolismALink - A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials
Qin Y, Tian Y, Liu X, et al. (2020). Experimental GerontologyADOI
Community Sources
Storage
Unopened
Store dry, at room temperature (15–25 °C), protected from light.
Opened
Keep container tightly closed; avoid moisture; store capsules and tablets as per unopened conditions.
Notes
Vaginal preparations (Intrarosa®) should be stored at ≤ 25 °C per the summary of product characteristics; do not freeze.